OVARIAN CANCER and US

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Friday, April 09, 2010

New study confirms HRT helps ward off colon cancer | Reuters



 Note: this issue of a protective effect was known at the time the original WHI study information was published but also received very little attention

 New study confirms HRT helps ward off colon cancer

Fri Apr 9, 2010 5:19pm EDT
NEW YORK (Reuters Health) - Hormone replacement therapy (HRT) cuts a woman's risk of developing colon cancer, new research confirms.

Millions of women stopped taking HRT when a Women's Health Initiative study showed in 2002 that the hormones raised the risk of stroke, heart disease and breast cancer.
But the Women's Health Initiative had also found that HRT protected against colon cancer. Some studies have also suggested that oral contraceptives might reduce the risk of the disease, while the fact that women are at lower risk of colon cancer than men also hints at a hormonal role in disease risk.
To investigate ties between HRT and colon cancer further, Dr. Millie D. Long of the University of North Carolina at Chapel Hill and her colleagues matched 443 women diagnosed between 2001 and 2006 with distal large bowel cancer (meaning tumors at the far end of the colon and the rectum) to 405 healthy control women. The average age of the study participants was around 63.
Long's team found that women who had ever used HRT were at half the risk of this type of colon cancer compared to women who'd never used hormone replacement, and the longer a woman was on HRT, the lower the risk.
For example, women who used hormones for less than four years cut their colon cancer risk by about one-quarter; four to eight years of HRT cut risk by a third; nine to 14 years of use halved risk; and 15 years or more of HRT reduced risk by two-thirds. The effects were the same for African-American women and white women.
However, there was no relationship between oral contraceptive use and colon cancer risk, the study team reports in the American Journal of Gastroenterology.
Long-term hormone therapy is no longer recommended for postmenopausal women, Long and her team note, although it is still sometimes prescribed on a short-term basis to help women with menopausal symptoms such as hot flashes. The major drop off in distal large bowel cancer in recent years could have been related to widespread use of HRT, the researchers say.
More research is needed to determine if HRT's protective effects persist after women stop taking hormones, the researchers add, or whether there might be a "rebound" effect with more pre-cancerous polyps developing after a woman halts
HRT.
"It may become important in the future to tailor timing of women's colorectal screening based on cessation of hormonal therapy," Long and her colleagues conclude.

SOURCE: The American Journal of Gastroenterology, online March 30, 2010.

Patented Genes - 60 Minutes - CBS News




North Carolina Man Denied Free Screening for Suspected Male Breast Cancer - ABC News




Gyn Congress 2010 Webcast - Novel Therapies (2) additonal videos free access



Session V: Ovarian Cancer III: Novel Therapies

* Emerging options in antiangiogenic targeted therapy for ovarian cancer
Andrew Clamp, MD, PhD

* Targeted therapy for ovarian cancer: Beyond angiogenesis
Stanley B. Kaye, MD

Gyn Congress 2010 Webcast Case-based approaches Recurrence (4) additional presentations/free access



Session IV: Ovarian Cancer II: A Case-Based Approach to Recurrence

* Interactive clinical case: non surgical Management of platinum sensitive ovarian cancer
Andreas du Bois, MD

* Interactive clinical case: Considerations for the management of a partially platinum sensitive relapse (6-12 months)
Bradley J. Monk, MD

* Interactive clinical case: Management of platinum resistant/refractory ovarian cancer
Eric Pujade-Lauraine, MD, PhD

* Keynote Lecture: Changing standards of care: The role of CA125 in the management of Ovarian Cancer
Gordon J.S. Rustin, MD, FRCP

Gyn Congress 2010 Webcasts (4) free online videos Surgery,systemic therapies,serous carcinomas



*State of the art surgical strategies in ovarian cancer: How to do it?
*State of the art surgical strategies in ovarian cancer: When to do it?
*Interactive clinical case: First-line systemic therapies for ovarian cancer
*Definition and characterization of low-grade and high-grade ovarian serous carcinomas

About consumer participation | Cochrane Consumer Network



Note: "prioritise topics for new reviews"
In response to a request from the Cochrane Network, ovarian cancer women/caregivers were asked to respond to a survey regarding priortisation. This was done, in part, through the ACOR Ovarian Cancer group (http://www.acor.org). A large response was received and the Cochrane Network responded in a positive manner.

 

About consumer participation

The authors of Cochrane reviews may consider a question for a review because of their own interests and experiences as a clinician or a healthcare researcher. These are not always the questions that are of most concern to healthcare consumers and their families and carers.
It is not easy for us, the public, to understand how the questions for Cochrane reviews need to be stated in order to be ‘answerable’ in research terms. You can learn more about this from our Training materials on the Resources webpage.
The purpose of consumer input during the review process is to:
  • ensure that a review question is relevant to people requiring health care and who are offered an intervention by their healthcare providers;
  • identify outcomes from healthcare interventions that are important for consumers – which may be different from those identified by service providers;
  • improve access to reviews by ensuring that the review can be read by a wide audience, and the language is sensitive to consumers;
  • weigh up the benefits of a healthcare intervention against the potential harms – from a healthcare user perspective;
  • prioritise topics for new reviews.

Healthcare users in Cochrane | Cochrane Consumer Network



Purpose
The World Health Organization (1978) states: The people have the right and duty to participate individually and collectively in the planning and implementation of their health care.
Our core function is to provide consumer input into developing Cochrane systematic reviews of best evidence in health care and in utilising this evidence.
The purpose of this website is to tell you about The Cochrane Collaboration and how we receivers and users of health care, parents and carers can benefit from its work..

"No one will own the problem" Departing oncologist cites frustration - Dr. Lizabeth Brydon Saskatchewan



"No one will own the problem and it is a problem," Brydon said. "The fact of my leaving puts more pressure on it. I realize by doing this I have created a crisis, but we've given them two drop-dead dates saying, 'We're closing our office here because we can't cope.' "

Young Adult Cancer Canada . Community . Profiles Amy young adult with ovarian cancer




Thursday, April 08, 2010

PennMed Clinical Trial: Phase 1/2a Study of DTA-H19 (IP) in Advanced Stage Ovarian Cancer With Symptomatic Ascites



Description This study is designed to assess the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy for ascites palliation of DTA-H19 administered intraperitoneally (IP) in subjects with advanced stage ovarian cancer who have evidence of symptomatic ascites

Investigators George Coukos, M.D., Ph.D., Principal Investigator University of Pennsylvania Medical Center Philadelphia, Pennsylvania 19104-6142

2010 full free access: Analysis - When Should Surgical Cytoreduction in Advanced Ovarian Cancer Take Place?



Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer - Cochrane Collaboration - review 2007



MPEG LA Launches Initiative to Make Gene Patents Available for Diagnostic Testing - MarketWatch



"By aggregating patent rights for existing and emerging tests that may lead to personalized treatment (e.g., hereditary hearing loss in infants, breast cancer, ovarian cancer, cardiovascular disease, Lynch syndrome) and licensing them nonexclusively for diagnostic use, MPEG LA's diagnostic genetics patent licensing facility, or "supermarket," will assist laboratories, testing companies and researchers in obtaining rights they need to design comprehensive diagnostic genetics tests that the market wants, thereby making these tests widely available through multiple channels at affordable prices."

Erythropoietin and Ovarian Cancer - Response. [Mol Cancer Ther. 2010] - PubMed result



Four new cases of double heterozygosity for BRCA1 ... [Breast Cancer Res Treat. 2010] - PubMed result



"Double heterozygosity (DH) for BRCA1 and BRCA2 mutations is a very rare finding, particularly in non-Ashkenazi individuals, and only a few cases have been reported to date. In addition, little is known on the pathological features of the tumors that occur in DH cases and on their family history of cancer. Four carriers of pathogenic mutations in both BRCA1 and BRCA2 were identified among women who underwent genetic counseling for hereditary susceptibility to breast and ovarian carcinoma at three different Italian institutions"

Ovacome :News survey on cancer related fatigue (online) - survey is cancer related fatigue not specific to ovarian cancer



Can you help with research on cancer related fatigue?
"This study on cancer fatigue is being carried out by researchers in the School of Psychology, Trinity College Dublin. The study is funded by the Irish Cancer Society and the Irish Research Council for Science Engineering and Technology."

March 2010

Researchers in Trinity College Dublin are investigating the causes of cancer fatigue and the factors that contribute to the development of chronic fatigue in some cancer patients. The study is funded by the Irish Cancer Society and the IRCSET 'Embark Initiative'.
Who can participate?
Anyone who (a) has been treated for cancer or is currently being treated for cancer and (b) is experiencing fatigue.
What does participation involve?
Participation involves filling in a number of questionnaires about your fatigue, the factors you believe contribute to your fatigue, and the coping strategies you use to manage this symptom.
How can I participate?
If you would like to participate please complete this online questionnaire: http://www.surveymonkey.com/s/CancerFatigueStudy

If you would prefer to complete the questionnaire in hard copy or if you would like further information, please contact the researcher: Maria Pertl (Phone: 01 896 3083 / E-mail: pertlm@tcd.ie).

news article: US & Canada - Maker of cancer test loses right to DNA patent



Note: references to France, UK and Europe

Quest PharmaTech completes critical review of development status for its recently acquired therapeutic antibody platform - Oregovomab + chemo trials..



"An 80 patient multicentre Italian cooperative trial will establish evidence for the clinical benefit associated with enhanced specific T cell immunity achievable by combining oregovomab with carboplatin and paclitaxel in the initial treatment of advanced ovarian cancer. Concurrent to this effort, a 30 patient Canadian clinical trial will evaluate the ability of a TLR-3 agonist to enhance the strength of the oregovomab immune response generated in the 'maintenance' setting in advanced ovarian cancer patients following front-line chemotherapy. The third clinical trial to be conducted in the U.S. will use gemcitabine, another cytotoxic agent, in a cohort of patients with CA125 associated resectable pancreatic cancer in combination with oregovomab."

""Successful completion of our clinical strategy will lead to a product for one or all treatment phases of advanced ovarian cancer, starting with front line treatment followed by watchful waiting and finally retreatment or initial treatment of recurrent disease."

"The additional antibodies in the platform (anti-MUC1, anti-PSA, anti-CA19.9 and anti-TAG 72) will undergo continuing preclinical development in anticipation of rapid clinical development once the initial oregovomab studies establish the validity of the combination therapy premise."

"Quest PharmaTech is developing the high affinity monoclonal antibody oregovomab (MAb B43.13) for the treatment of ovarian cancer. Oregovomab targets the circulating tumour-associated antigen CA125."

Edmonton, Alta news item: Abnormal results don't always mean cancer (references robotic surgery)



"The Gynecologic Oncology Service at the Lois Hole Hospital for Women looks after patients from all over northern Alberta, the Arctic (Nunavut) and parts of northern B.C. Women initially seen at the Cross Cancer Institute with cervical, endometrial or ovarian cancer that require surgery will have it performed at the Lois Hole Hospital for Women."

Wednesday, April 07, 2010

U.S. Patient Advocate Foundation :: 1-800-532-5274



YouTube - Current Topics in Genome Analysis 2010



Note: Very long but interesting video - 1 1/2 hrs. The subject matter sounds very technical but the content is in good plain english language - talks about unresolved side effects, patient concerns....


http://www.youtube.com/watch?v=IMeJA_inoEM

GenomeTV — March 29, 2010 — March 23, 2010
Howard McLeod, Pharm.D.
Current Topics in Genome Analysis 2010

Validation of the pedigree assessment tool (PAT) in families with BRCA1 and BRCA2 mutations



CONCLUSIONS: In overall performance, the PAT is at least comparable to the Myriad II and Penn II models in screening women appropriate for genetic referral. Simplicity and identification of families with non-BRCA hereditary BC syndromes suggest that the PAT is better suited for BC risk screening.

Ovarian cancer: predictors of early-stage diagnosis - California Cancer Registry



"CONCLUSION: These findings suggest that, in addition to tumor biology, disparities in access to care may have a significant effect on the timely diagnosis of epithelial ovarian cancer."

Cancer Causes Control. 2010 Apr 3. [Epub ahead of print]
Ovarian cancer: predictors of early-stage diagnosis.
Morris CR, Sands MT, Smith LH.
California Cancer Registry, Public Health Institute, California Department of Public Health, 1825 Bell St., Suite 102, Sacramento, CA, 95825, USA, cmorris@ccr.ca.gov.

Bridging the Gap between Cytotoxic and Biologic Therapy with Metronomic Topotecan and Pazopanib in Ovarian Cancer



"Pazopanib therapy in combination with metronomic topotecan therapy showed significant antitumor and antiangiogenic properties in preclinical ovarian cancer models and warrants further investigation as a novel therapeutic regimen in clinical trials."

(abstract) Review: The use of proteomics as a research methodology for studying cancer-related fatigue: a review



Note: limited information in the abstract

JNCI Editorial: Fruits, Vegetables, and Cancer Prevention: Turmoil in the Produce Section



Some key excerpts - full text of Editorial available without cost:
  •  In this issue of the Journal, Boffetta et al. (6) report findings from a European cohort of nearly 400 000 men and women who developed approximately 30 000 cancers at all sites combined over nearly 9 years of follow-up. After accounting for measurement error, a very weak but statistically significant inverse association was seen—a 4% lower incidence of all cancers combined for an increment of 200 g of total fruits and vegetables per day, which corresponds to about two extra servings per day.
  • Most fundamentally, this study strongly confirms the findings from other prospective studies that the results of case–control studies were overly optimistic and that any association of intake of fruits and vegetables with risk of cancer is weak at best.
  • Their more detailed analyses suggesting a stronge rbenefit among heavier consumers of alcohol lend some weight to a causal interpretation because other studies (7,8) have suggested that folate, primarily from fruits and vegetables,may be more beneficial in the context of regular alcohol consumption.
  • A very weak or undetectable association between fruits and vegetables and risk of cancer does not exclude the possibility that oneor a small group of fruits or vegetables, or a specific substance in some of these foods, has an important protective effect.
  • Even if we assume that the weak association seen in the EPIC cohort represents a true protective effect of fruits and vegetables,the question would still remain whether an effect of this magnitude should lead to clinical interventions or public health actions.Conveniently, although the evidence for benefits of fruits and vegetables against cancer was waning, data supporting benefits for cardiovascular disease were accumulating.
  •  In summary, the findings from the EPIC cohort add further evidence that a broad effort to increase consumption of fruits and vegetables will not have a major effect on cancer incidence.


Fruit and Vegetable Intake and Overall Cancer Risk in the European Prospective Investigation Into Cancer and Nutrition (EPIC) - JNCI abstract



Abstract:
Conclusions: A very small inverse association between intake of total fruits and vegetables and cancer risk was observed in this study. Given the small magnitude of the observed associations, caution should be applied in their interpretation.

CONTEXT AND CAVEATS
Prior knowledge
The association between high intake of fruits and vegetables and reduction in overall cancer risk is not conclusively established.
Study design
European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study was conducted between 1992 and 2000. Diet and lifestyle data were self-reported by the participants. Cancer incidence and mortality data were obtained from country-specific national and regional registries. Association between overall cancer risk and high intake of total fruits, total vegetables, and total fruits and vegetables combined was assessed. Estimated cancer risks were adjusted for smoking, alcohol consumption, and many other variables.
Contribution
High intake of vegetables, and fruits and vegetables combined, was associated with a small reduction in overall cancer risk. The association was stronger in heavy alcohol drinkers but was restricted to cancers caused by smoking and drinking.
Implications
This study reveals a very modest association between high intake of fruits and vegetables and reduced risk of cancer.
Limitations
The inverse association between overall cancer risk and high intake of fruits and vegetables was weak. Errors inherent to self-reported dietary habits may have resulted in bias.
From the Editors

BBC News - Five-a-day has little impact on cancer, study finds




Ontario Medical Association-patients share your views




Tuesday, April 06, 2010

An open-label, non-randomized comparison of venlafaxine and gabapentin as monotherapy or adjuvant therapy in the management of neuropathic pain in patients with peripheral neuropathy



Note:

*click on 'pdf' to access the full paper (free)
* this paper is not specific to neuropathy as a treatment related adverse effect of cancer therapies
* it is written in fairly easy to understand language
* discusses side effects

Who owns your genes? video/news item - FORCE/Myriad



NCI Improving the Efficiency of Clinical Trials: Decreasing Activation Times by Fifty Percent



NCI Scientists Restore DNA Repair in Mice with BRCA1 Gene Mutations



Soy won't reduce cholesterol after menopause: MedlinePlus



Save the Date: Living with Lynch Syndrome An Update for Families with HNPCC - Mayo, Rochester



Save the Date: Living with Lynch Syndrome: An Update for Families with HNPCC

June 27, 2009, 10 a.m. -3 p.m., Mayo Clinic, Rochester

This half-day educational program will offer a variety of topics focusing on Lynch syndrome—also known as Hereditary Non-Polyposis Colorectal Cancer (HNPCC)—from the biological basis of the condition and psychological impact of a diagnosis to practical health care tips.

The program is designed for people living with Lynch syndrome, their family members, and interested health care professionals. Patients and families will be able to expand their knowledge, network with one another, and share their experiences. Anna Leininger, M.S., C.G.C., Minnesota Colorectal Cancer Initiative coordinator and consultant to the Masonic Cancer Center's William C. Bernstein MD Familial Cancer Registry, will be one of the presenters at the program.

The program is hosted by Mayo Clinic; organizing sponsors include the William C. Bernstein MD Familial Cancer Registry, HealthEast Cancer Care, and the Colon Cancer Coalition. Cost is $20 per person; $35 per couple; and $50 per family (up to 5 members). For more information or to register, call 507-284-2241 or e-mail canceredprog@mayo.edu

Awareness Day: Living with Lynch Syndrome : BC Cancer Agency June 12th Vancouver, B.C.




High-risk patients with hematuria are not evaluated according to guideline recommendations




CA 125: Value or addiction?. Patricia A. Goldman. 2010; Cancer



Note: journal article by paid subscription

Commentary
CA 125: Value or addiction?
Patricia A. Goldman, BA *
President Emerita, Ovarian Cancer National Alliance, Washington, DC
*Correspondence to Patricia A. Goldman, Ovarian Cancer National Alliance, 910 17th Street, NW, Suite 1190, Washington, DC 20006; Fax: (202) 331-2292

Abstract
The author challenges a recent study indicating that there is no apparent benefit in routinely measuring cancer antigen 125 (CA 125) in the follow-up of women with ovarian cancer.

UICC International Union Against Cancer - A call to action (petition)



What is the World Cancer Declaration?
  • Launched in 2006 and revised in 2008, the World Cancer Declaration is a call to action to substantially reduce the global cancer burden by 2020.
  • It was developed by international cancer control advocates to bring the cancer crisis to the attention of policymakers worldwide.
  • It lays out an ambitious set of 11 targets and action plan to stop and reverse current trends.
  • It was unanimously adopted at the World Leader’s Summit of policymakers, leaders & health experts during the 2008 World Cancer Congress in Geneva, Switzerland.
  • UICC is the “custodian” of the World Cancer Declaration and prioritizes development of a comprehensive response.

press release: Oregovomab: Quest PharmaTech Discloses Cancer Immunotherapy Development Strategy




press release: Driven by the Approval and Rapid Uptake of Avastin, the Ovarian Cancer Drug Market Will More Than Triple to Nearly $1.5 Billion in 2018



avastin

The 10th International Conference on Integrated Care conference notice: Tampere, Finland, INIC10




Sexual Morbidity Associated With Poorer Psychological Adjustment Among Gynecological Cancer Survivors



Note: excerpts from abstract

Objectives: Sexual morbidity is a distressing and undertreated problem in gynecological cancer survivorship known to occur early and persist well beyond the period of physical recovery.

Sexual Morbidity Associated With Poorer Psychological Adjustment Among Gynecological Cancer Survivors



Note: excerpts from abstract

Objectives: Sexual morbidity is a distressing and undertreated problem in gynecological cancer survivorship known to occur early and persist well beyond the period of physical recovery.
Methods: A cross-sectional design was used. The participants were gynecological (cervical, endometrial, ovarian, and vulvar) cancer survivors who were partnered (N = 186), whose cancer was diagnosed 2 to 10 years previously, and who were at least 6 months post any cancer therapy. Most had been found to have early-stage disease (70%) and were treated with hysterectomy (77%), chemotherapy (43%), and/or radiotherapy (23%).
Conclusions: These findings suggest that prevention or treatment of sexual morbidity might foster improved psychological adjustment/QoL. Given the high rates of sexual morbidity in this population and the connection between sexuality and broader psychological adjustment/QoL, there is a clear need for better integration of sexuality rehabilitation into routine clinical care.

Fecal Incontinence Affecting Quality of Life and Social Functioning Among Long-Term Gynecological Cancer Survivors



Conclusions: Among gynecological cancer survivors having undergone pelvic radiotherapy alone or as part of a combined treatment, fecal incontinence is associated with social, psychological, sexual, and functional consequences.

Follow-Up Study of the Correlation Between Postoperative Com... : International Journal of Gynecological Cancer



Follow-Up Study of the Correlation Between Postoperative Computed Tomographic Scan and Primary Surgeon Assessment in Patients With Advanced Ovarian, Tubal, or Peritoneal Carcinoma Reported to Have Undergone Primary Surgical Cytoreduction to Residual Disease of 1 cm or Smaller

Conclusions: On this follow-up analysis, only age, stage, and residual disease were significant prognostic factors for overall survival. Discordant findings between the primary surgeon's assessment and the postoperative CT scan findings of residual disease was not an independent prognostic factor.

econdary Surgery in Patients With Serous Low Malignant Potential Ovarian Tumors With Peritoneal Implants



Conclusions: Secondary surgery seems to reduce the risk of recurrence in patients with serous LMPOT and peritoneal implants. Patients with residual disease are probably those likely to benefit from such surgery. Further studies are needed to confirm these preliminary results.

Lymph Node Metastasis in Grossly Apparent Stages I and II Epithelial Ovarian Cancer



Conclusions: Based on diagnostic value, the result suggests that the role of lymphadenectomy might differ by histological type, as its therapeutic effect might be unclear. A multicenter analysis is essential for confirmation

Agency for Healthcare Research and Quality - Questions Are the Answer: Build Your Question List



Note: general

Physician-Ownership Of Ambulatory Surgery Centers Linked To Higher Volume Of Surgeries -- Health Affairs



Intraperitoneal Paclitaxel as Consolidation Treatment in Ovarian Cancer Patients: A Case Control Study



Conclusion: Weekly IP consolidation chemotherapy with paclitaxel 60 mg/mq is well tolerated and, in this experience, a prolongation of progression-free survival was observed.

abstract: Population-Based Study of the Risk of Second Primary Contralateral Breast Cancer Associated With Carrying a Mutation in BRCA1 or BRCA2



Results: Compared with noncarriers, BRCA1 and BRCA2 mutation carriers had 4.5-fold (95% CI, 2.8- to 7.1-fold) and 3.4-fold (95% CI, 2.0- to 5.8-fold) increased risks of contralateral breast cancer, respectively. The relative risk of contralateral breast cancer for BRCA1 mutation carriers increased as age of first diagnosis decreased. Age-specific cumulative risks are provided for clinical guidance.

Conclusion:
The risks of subsequent contralateral breast cancer are substantial for women who carry a BRCA1/BRCA2 mutation. These findings have important clinical relevance regarding the assessment of BRCA1/BRCA2 status in patients with breast cancer and the counseling and clinical management of patients found to carry a mutation.

abstract: Apr 5, 2010: Development of a Multimarker Assay for Early Detection of Ovarian Cancer -- JCO



Note: accompanying Editorial notes that this study was comprised of postmenopausal women only
                                    ******************
JCO Early Release, published online ahead of print Apr 5 2010
Journal of Clinical Oncology, 10.1200/JCO.2008.19.2484

Received August 3, 2008
Accepted January 5, 2010

Development of a Multimarker Assay for Early Detection of Ovarian Cancer (reference link for authors)

Purpose: Early detection of ovarian cancer has great promise to improve clinical outcome.
Patients and Methods: Ninety-six serum biomarkers were analyzed in sera from healthy women and from patients with ovarian cancer, benign pelvic tumors, and breast, colorectal, and lung cancers, using multiplex xMAP bead-based immunoassays. A Metropolis algorithm with Monte Carlo simulation (MMC) was used for analysis of the data.
Results: A training set, including sera from 139 patients with early-stage ovarian cancer, 149 patients with late-stage ovarian cancer, and 1,102 healthy women, was analyzed with MMC algorithm and cross validation to identify an optimal biomarker panel discriminating early-stage cancer from healthy controls. The four-biomarker panel providing the highest diagnostic power of 86% sensitivity (SN) for early-stage and 93% SN for late-stage ovarian cancer at 98% specificity (SP) was comprised of CA-125, HE4, CEA, and VCAM-1. This model was applied to an independent blinded validation set consisting of sera from 44 patients with early-stage ovarian cancer, 124 patients with late-stage ovarian cancer, and 929 healthy women, providing unbiased estimates of 86% SN for stage I and II and 95% SN for stage III and IV disease at 98% SP. This panel was selective for ovarian cancer showing SN of 33% for benign pelvic disease, SN of 6% for breast cancer, SN of 0% for colorectal cancer, and SN of 36% for lung cancer.
Conclusion: A panel of CA-125, HE4, CEA, and VCAM-1, after additional validation, could serve as an initial stage in a screening strategy for epithelial ovarian cancer.

Editorial: A Step Forward for Two-Step Screening for Ovarian Cancer - Journal of Clinical Oncology



A Step Forward for Two-Step Screening for Ovarian Cancer
  Martee L. Hensley, Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY

See accompanying article doi: 10.1200/JCO.19.2484

Ovarian Cancer and Our Pets -Cheryl's family has just been added!



'Ovarian Cancer and Our Pets' Montage (video) free to view - no passwords needed - just click on the link

Monday, April 05, 2010

NHGRI Names New Chief of Genome Technology Branch, April 5, 2010 News Release - National Institutes of Health (NIH) U.S.



"Dr. Brody has headed GTB's Molecular Pathogenesis Section, investigating genetic variants that lead to changes in normal metabolic pathways to cause cancer and birth defects. He has made key discoveries regarding the genetics of breast cancer and neural tube defects. For example, the Brody laboratory was among the first to report that women who carry mutations in the BRCA1 or BRCA2 genes are at a higher risk of developing both breast cancer and ovarian cancer compared to women without such mutations. In addition, his group was the first to report that the frequency of specific BRCA1 and BRCA2 gene mutations are elevated in the Jewish population. In collaboration with scientists at Howard University, Washington, D.C., he described a series of mutations and rare variants in BRCA1 carried by some African-American women with breast and ovarian cancer."

uTube - Bradley J. Monk, MD, University of California Irvine talks about early stage ovarian cancer including clear cell SGO



Note: the title on this video is wrong

utube: Thomas J. Herzog, MD, Columbia University College of Physicians and Surgeons talks about liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced malignancy SGO



Thomas J. Herzog, MD, Columbia University College of Physicians and Surgeons talks about liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced malignancy.

utube - Deborah Armstrong, MD, Johns Hopkins Kimmel Cancer Center, discusses Early studies of enzastaurin and bevacizumab.SGO




utube video - Robert L. Coleman, MD/M. D. Anderson Cancer Center talks about intraperitoneal versus intravenous chemotherapy in ovarian cancer SGO




» Blog Archive » WORD Goes To SGO (+ video)




Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas



OBJECTIVE: To evaluate drug resistance after exposure to neoadjuvant chemotherapy and to postoperative chemotherapy in epithelial ovarian, fallopian, and primary peritoneal carcinomas.

Reminder: A patient's perspective on ovarian cancer as a chronic disease—Devaluing a survivor's challenge Caridad Vera-Garcia



Note: Cary is now with us 'in spirit'

Is the current concept of recurrent ovarian carcinoma as a chronic disease also applicable in platinum resistant patients?



Note: the authors' opinions confirm ovarian cancer as a chronic disease

full free access: COMMENTARY Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors






"Inhibiting angiogenesis is an effective approach to cancer therapy, but it has been associated with cardiovascular toxic effects. At times, adverse events such as hypertension and heart failure have led to treatment cessation and even life-threatening consequences. Cancer patients have often been excluded from studies of cardiovascular disease, and patients with clinically significant cardiovascular disease have been excluded from studies of new cancer therapies. Consequently, the capacity for determining the incidence or prevalence of cardiovascular toxic effects of anticancer agents and to determine their optimal management has been limited. Oncologists and cardiovascular medicine specialists have increasingly recognized that the prevention and management of these toxic effects is important for these potentially life-sustaining anticancer agents to benefit the greatest possible number of patients."
 
Box 1. Summary recommendations

HE4: a new potential early biomarker for the recurrent ovarian cancer



"The follow-up study showed an increase of HE4 5-8 months before CA125 increment in five of the eight patients, this early expression being strictly associated to a relapse of the disease. In conclusion, this study showed that HE4, compared to CA125, potentially is a better marker for the diagnosis of OC and could be an important early indicator of the recurrence of the disease."

Epidemiologic evidence on coffee and cancer



Nutr Cancer. 2010 Apr;62(3):271-83.
Epidemiologic evidence on coffee and cancer.

Arab L.
David Geffen School of Medicine, University of California, Los Angeles, USA.

Coffee consumption is a major and frequent dietary exposure in diverse cultures around the globe whose safety has been questioned. A substantial body of epidemiologic evidence, consisting of over 500 papers relating the consumption of coffee to cancer of various sites, has accumulated to date. Numerous individual, site-specific meta analyses have been undertaken at various times. However, there is no comprehensive, up-to-date overview of the entirety of the knowledge base. To address this need, this review summarized the findings of the meta analyses and recent papers on site-specific human cancers among coffee consumers. For hepatocellular and endometrial cancers, there appears to be a strong and consistent protective association; for colorectal cancer, the direction of association is borderline protective. There appears to be no association with breast, pancreatic, kidney, ovarian, prostate, or gastric cancer. Risk of bladder cancer appears to be associated with heavy coffee consumption in some populations and among men. The associations with childhood leukemia and mother's consumption of coffee were ambiguous-with some suggestion of risk at high levels of daily consumption.

PMID: 20358464 [PubMed - in process]

Development of a culturally tailored genetic counseling booklet about hereditary breast and ovarian cancer for Black women.




Clinical Trials Canada - preformated search



Search - preformated - Ovarian / Fallopian Tube / Peritoneal = 58 clinical trials
Note:
1) results are not necessarily specific to Ovarian/FT/P cancer but include differing tumor types (cancers)  e.g.phase 1;
2) should be cross referenced to http://www.clinicaltrials.gov for potential duplications/excluded/not included

Mice get new role in search for cancer drugs - The Boston Globe



Note: includes public comments

DOD (patient safety) Defense.gov News Article: Officials Step Up Patient Safety Efforts



“It’s OK to make and identify an error,” he added, “It’s not OK to cover up an error.”

Study: Patient Safety Incidents at U.S. Hospitals Show No Decline, Cost $9 Billion - financial news



The following are the 15 patient safety indicators studied:

Complications of anesthesia
Death in low mortality Diagnostic Related Groupings (DRGs)
Decubitus ulcer (bed sores)
Death among surgical inpatients with serious treatable
complications
Iatrogenic pneumothorax
Selected infections due to medical care
Post-operative hip fracture
Post-operative hemorrhage or hematoma
Post-operative physiologic and metabolic derangements
Post-operative respiratory failure
Post-operative pulmonary embolism or deep vein thrombosis
Post-operative sepsis
Post-operative abdominal wound dehiscence
Accidental puncture or laceration
Transfusion reaction

Insight on Variables Leading to Burnout in Cancer Physicians



abstract

Requests for Cancer Prevention Information: The Cancer Information Service (2002–2006)



NIH Senior Health: Life After Cancer - Table of contents



Pallimed: A Hospice & Palliative Medicine Blog: Palliative Care: An Unnecessary Specialty.



Sick leave of spouses to cancer patients before and after diagnosis - abstract



abstract: pre-clinical - A Novel Breast/Ovarian Cancer Peptide Vaccine Platform That Promotes Specific Type-1 but not Treg/Tr1-type Responses - DepoVax



DepoVax

Agendia Launches BluePrint(TM) Expanding Breast Cancer Product Offering - media article



"HUNTINGTON BEACH, California and AMSTERDAM, March 24, 2010 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that its breast cancer product offering, consisting of breast cancer recurrence test MammaPrint(R), and TargetPrint(TM), has been expanded with BluePrint (TM) to report important additional information on tumor subtypes. This new service is based on an 80-gene signature that identifies the basal-like, luminal-like, and HER2 molecular subtypes in breast cancer tumors...."

free full access: A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer.



for full free access click on 'pdf'

Search of: ovarian cancer | Open Studies | received from 03/01/2010 to 04/05/2010 - List Results - ClinicalTrials.gov



12 new clinical trials listed - search terms: ovarian cancer | Open Studies | received from 03/01/2010 to 04/05/2010

Rank Status Study
1  Not yet recruiting Seprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of Therapy in Women Undergoing Staging and Intraperitoneal Chemotherapy for Advanced Ovarian Cancer

2  Recruiting Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Ovarian Cancer and Inoperable Malignant Bowel Obstruction
Conditions: Ovarian Cancer; Bowel Obstruction

3  Recruiting Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer

4  Not yet recruiting Irinotecan and Bevacizumab for Recurrent Ovarian Cancer
Condition: Ovarian Cancer

5  Recruiting MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
Conditions: Ovarian Carcinoma; Fallopian Tube Cancer; Peritoneal Cancer; Breast Carcinoma

6  Not yet recruiting First-line Treatment of Weekly Paclitaxel With Carboplatin and Bevacizumab in Ovarian Cancer
Conditions: Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer

7  Recruiting Collection of Tissue Samples From Patients With Stage III or Stage IV Ovarian Epithelial Cancer
Condition: Ovarian Cancer

8  Not yet recruiting Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
Conditions: Cognitive/Functional Effects; Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer

9  Recruiting Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer
Conditions: Bladder Cancer; Cervical Cancer; Colorectal Cancer; Endometrial Cancer; Gastrointestinal Complications; Long-term Effects Secondary to Cancer Therapy in Adults; Ovarian Cancer; Prostate Cancer; Radiation Toxicity; Sarcoma; Testicular Germ Cell Tumor; Vaginal Cancer

10  Recruiting A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
Conditions: Ovarian Neoplasms; Breast Neoplasms; Prostatic Neoplasms
Intervention: Biological: DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG

11  Recruiting Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
Conditions: Fallopian Tube Cancer; Ovarian Sarcoma; Ovarian Stromal Cancer; Recurrent Cervical Cancer; Recurrent Endometrial Carcinoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Uterine Sarcoma; Recurrent Vaginal Cancer; Recurrent Vulvar Cancer; Stage III Cervical Cancer; Stage III Endometrial Carcinoma; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage III Uterine Sarcoma; Stage III Vaginal Cancer; Stage III Vulvar Cancer; Stage IV Endometrial Carcinoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Uterine Sarcoma; Stage IV Vulvar Cancer; Stage IVA Cervical Cancer; Stage IVA Vaginal Cancer; Stage IVB Cervical Cancer; Stage IVB Vaginal Cancer

12  Recruiting Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats
Conditions: Ovarian; Breast; Prostate; Pancreatic; Advanced Tumours

Announcement: Annual International Gathering - Ovarian Cancer/ACOR



Further information/registration (free): http://www.ocats.ca

Saturday, April 03, 2010

Credit where credit is due? Regulation, research integrity and the attribution of authorship in the health sciences



How accurate are cancer cell lines? : Nature News



"Some argue that tumour cells obtained directly from patients are the best way to study cancer genomics."

The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment



Review

The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment

Surveillance for the detection of recurrent ovarian cancer: Survival impact or lead-time bias?



Objective

To compare the survival impact of diagnosing recurrent disease by routine surveillance testing versus clinical symptomatology in patients with recurrent epithelial ovarian cancer (EOC) who have achieved a complete response following primary therapy.

Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: An updated series



Abstract 
Objective Surgical cytoreduction is an integral therapeutic modality for patients with epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal (PPC) cancer in the primary setting. The role of surgical cytoreduction in the recurrent setting is not clearly defined and remains controversial. The objective of this study was to assess this potential survival benefit in a large cohort of patients with a long follow-up period.  

Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: The big picture



"We propose that future international cooperation should aim at a uniform pooled analysis of the wealth of ovarian cancer array data already available. This will enhance the power of each separate ovarian cancer study and can lead to promising results."

PET/MRI: paving the way for the next generation of clinical multimodality imaging applications.



The Psychosocial Oncology Learning Assessment: A Province-Wide Survey of Cancer Care Providers' Learning Needs



"This research suggests that cancer care providers are interested in learning more about the psychosocial issues related to cancer care."

Familial Risk of Cancer and Knowledge and Use of Genetic Testing



MAIN MEASURES: Familial cancer risk was estimated based on the number of first-degree relatives with a breast and ovarian cancer syndrome (BRCA)- or a Lynch-associated cancer, age of onset (<50 or >/=50 years), and personal history of any cancer.
CONCLUSIONS: These nationally representative data provide estimates of the prevalence of familial cancer risk in the US and suggest that information about genetic testing is not reaching many at higher risk of inherited cancer.

Chemotherapy use and risk of bone marrow suppression in a large population-based cohort of older women with breast and ovarian cancer.



Med Oncol. 2010 Apr 2

Division of Epidemiology and Disease Control, University of Texas School of Public Health, 1200 Herman Pressler Drive, RAS-E631, Houston, TX, USA.

We studied 65,521 women with breast cancer and 7,420 women with ovarian cancer aged >/= 65 identified from the 16 areas of the Surveillance, Epidemiology and End Results program linked with Medicare data during 1991-2002. Bone marrow toxicity associated with chemotherapy was defined using diagnosis codes from Medicare inpatient, outpatient and physician claims. The time to event Cox regression was utilized to estimate the risk of bone marrow toxicity. Use of anthracyclines, taxanes or platinums was associated with increased risks of short- (3 months) anemia and neutropenia in patients with breast cancer. Alkylating agents or antimetabolites were additional significant predictors of anemia in women with ovarian cancer. Patients who received chemotherapy (irrespective of regimens) were twice (breast cancer) or three times (ovarian cancer) as likely to develop thrombocytopenia compared to those not receiving chemotherapy. Among women with breast cancer, patients receiving cyclophosphamide, methotrexate and fluorouracil regimens (hazard ratio = 19.0, 95% CI = 11.2-32.5), platinum/taxane therapy (21.9, 11.9-40.4) or the cyclophosphamide, adriamycin and fluorouracil regimen (32.5, 19.6-53.9) were strongly associated with risk of aplastic anemia. There was a dose-response relationship between the use of taxane or platinum and the risk of bone marrow suppression, whereas the increased risk of bone marrow toxicity was consistently higher in those with use of alkylating agents or anthracycline-based regimens irrespective of the increasing number of cycles received. In conclusion, there was an association between chemotherapy use and clinical manifestations of bone marrow toxicities in a population-based setting.

Merck KGaA - EU regulator calls for review of Erbitux (cetuximab) / cancer vaccine Stimuvax (BLP25 liposome vaccine)



Safety concerns: 
1) Erbitux (cetuximab)
2) cancer vaccine Stimuvax (BLP25 liposome vaccine)

Thursday, April 01, 2010

Canadian Health Reference Guide - Saskatchewan Government and Health System Partners Release Plan to Improve Surgical Care



Note: no specific mention of ovarian cancer

Curis to Present at the 17th Annual Future Leaders in the Biotech Industry Conference - Hedgehog Pathway inhibitor GDC-0449 (financial news)



"Dan Passeri, Curis' President and Chief Executive Officer, will provide an overview of the status of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor. GDC-0449 is currently being developed in three Phase II clinical trials by Curis' collaborator Genentech, including in a pivotal Phase II trial in advanced basal cell carcinoma and Phase II trials in metastatic colorectal cancer and advanced ovarian cancer. Mr. Passeri will also discuss CUDC-101, Debio 0932 and Curis' other targeted cancer programs, in addition to other corporate activities.

There will be a corresponding webcast of the presentation, which can be accessed by visiting:

http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=CRIS&item_id=2957649

The presentation will be archived shortly after the live event and available for 30 days following the conference. In addition, it will be available for 30 days on the Investor Relations section of the Curis website at www.curis.com."

Best Evidence Interview: Use of Some SSRIs With Tamoxifen Increases Mortality in Breast Cancer Patients: A Best Evidence Interview With Catherine Kelly, MD



Note: included in interview is discussion of U.S./Canadian/Global research on this subject matter (reminder: Medscape articles are freely accessible with registration)

Cost Consciousness in Patient Care — What Is Medical Education’s Responsibility? NEJM




Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary



Abstract  
Background: Ixabepilone is a semisynthetic epothilone B analogue that is active in taxane-resistant cell lines and has shown activity in patients with refractory breast and ovarian cancer. We carried out a phase I trial of ixabepilone plus pegylated liposomal doxorubicin (PLD) in patients with advanced taxane-pretreated ovarian and breast cancer.

Wednesday, March 31, 2010

Analgesic Use Linked to Lower Estrogen Levels in Postmenopausal Women



Note: very preliminary/requires further research/article discusses primarily breast cancer/many limitations in study

Physicians' Awareness and Attitudes Toward Decision Aids for Patients With Cancer



Early Release, published online ahead of print Mar 30 2010
Journal of Clinical Oncology, 10.1200/JCO.2009.25.2874

Physicians' Awareness and Attitudes Toward Decision Aids for Patients With Cancer

Chantalle Brace, Selina Schmocker, Harden Huang, J. Charles Victor, Robin S. McLeod, and Erin D. Kennedy*
From the Department of Surgery, University Health Network–Toronto General Hospital; Department of Surgery, Mount Sinai Hospital; Dr Zane Cohen Digestive Disease Research Unit; and Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

Purpose:
Patient decision aids are interventions designed to help patients make deliberative choices about their treatment options and have been shown to significantly improve patient outcomes. Although considered optimal, decision aids are not widely used in clinical practice for cancer treatment. The objectives of this study are to determine physicians' awareness and use of decision aids, physicians' perceptions of the major barriers to the use of decision aids, and physician characteristics predictive of use of decision aids in clinical practice.

Adhesions and incisional hernias following laparoscopic versus open surgery for colorectal cancer in the CLASICC trial



Note: colorectal cancer study but similar surgical complications

CONCLUSION: Although this study has not confirmed that laparoscopic surgery reduces rates of AIO and IH (incisional hernia)after colorectal cancer surgery, trends suggest that a reduction in conversion to open surgery and elimination of port-site hernias may produce such an effect.

Modified midline abdominal wound closure technique in complicated/high risk laparotomies



CONCLUSION: Patients with extensive widespread generalized peritonitis and metastatic abdominal tumours need special attention regarding wound closure. This modified technique of midline abdominal wound closure is associated with low incidence of wound dehiscence and incisional hernia formation.

Phase I clinical trials in 85 patients with gynecologic cancer: The M. D. Anderson Cancer Center experience.



Surgical Procedures and Morbidities of Diaphragmat... [J Am Coll Surg. 2010] - PubMed result



Surgical Procedures and Morbidities of Diaphragmatic Surgery in Patients Undergoing Initial or Interval Debulking Surgery for Advanced-Stage Ovarian Cancer.

Hernia: MedlinePlus Medical Encyclopedia



Note: This is a very basic and general article.

Editorial: Highlighting the Science of Cancer Prevention — Cancer Prevention Research



Determinants of quality of life in patients with advanced cancer.



A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies



Translational research in the Gynecologic Oncology



Tuesday, March 30, 2010

Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial



Clinical Care Options - CME - Dr Maurie Markman updated CME March 3, 2010



Note: requires Password/Registration (free):

Oncology - Ovarian Cancer
Authors: Maurie Markman, MD
Date Released: October 01, 2009
Last Updated: March 03, 2010

full access: The Art of Oncology: Life's Lessons Lost...and Learned -- Journal of Clinical Oncology




Taking Stock After Gene Patents Are Invalidated - NYTimes.com Andy Pollack




Potential Role of Lymphadenectomy in Advanced Ovarian Cancer: A Combined Exploratory Analysis of Three Prospectively Randomized Phase III Multicenter Trials - Journal of Clinical Oncology



"Purpose:  Primary surgery followed by platinum/taxane-based chemotherapy is the standard therapy in advanced ovarian cancer. The prognostic role of complete debulking has been well described; however, the impact of systematic pelvic and para-aortic lymphadenectomy and its interaction with biologic factors are still not fully defined.
Conclusion:  Lymphadenectomy in advanced ovarian cancer might offer benefit mainly to patients with complete intraperitoneal debulking. However, this hypothesis should be confirmed in the context of a prospectively randomized trial."

Outcomes of Fertility-Sparing Surgery for Stage I Epithelial Ovarian Cancer: A Proposal for Patient Selection - Journal of Clinical Oncology



"Forty-five (53.6%) of 84 patients who were nulliparous at fertility-sparing surgery and married at the time of investigation gave birth to 56 healthy children."
"Conclusion: Our data confirm that fertility-sparing surgery is a safe treatment for stage IA patients with favorable histology and suggest that stage IA patients with clear cell histology and stage IC patients with favorable histology can be candidates for fertility-sparing surgery followed by adjuvant chemotherapy."

Genetic Alliance Webinars Schedule | Genetic Alliance



Genetic Alliance Webinars Schedule | Genetic Alliance



2010 Annual Conference Scholarships Genetic Alliance



Note: some partial sponsorships available Submit your application by May 10th, 2010. We will respond to your request by May 17th, 2010.

Creighton University Dr Henry Lynch Earns National Award for Lifetime Work in Hereditary Cancer



"Lynch has long been considered a pioneer in the field of hereditary cancer research and prevention. As an internal medicine resident in the 1960s, Lynch met patients who had many family members who were affected by or had died from the same type of cancer; he hypothesized the cancer could be triggered by hereditary factors. That launched a lifelong pursuit to uncover genetic links to certain types of cancer that, at the time, his peers thought to be triggered almost solely by environmental causes.

In the 1970s, Lynch was the first to describe a hereditary breast ovarian cancer syndrome, findings that led to the identification of the BRCA1 and BRCA2 germline mutations that predispose women to this syndrome. Hereditary nonpolyposis colorectal cancer (HNPCC), the most common form of hereditary colorectal cancer, is named after him as the Lynch syndrome."

Immunovaccine Begins Patient Recruitment for Phase 1 Trial of DPX-0907 Cancer Vaccine - MarketWatch



press release
March 29, 2010
Immunovaccine Begins Patient Recruitment for Phase 1 Trial of DPX-0907 Cancer Vaccine

HALIFAX, NOVA SCOTIA, Mar 29, 2010 -- Immunovaccine Inc. today announced that it has started screening patients for its Phase 1 clinical trial, investigating the company's therapeutic cancer vaccine, DPX-0907, as a treatment for patients with advanced stage breast, ovarian and prostate cancer. The primary goal of the trial is to establish the safety of the vaccine candidate which includes the DepoVax(TM) delivery platform. Secondary goals include an evaluation of dosing and an assessment of immune response.

Power Of Doctors Makes Elderly Patients Passive, Swedish Study Finds




Commentary: Estimating cancer survival--which is the right approach? -- Rachet and Coleman 39 (2): 611 -- International Journal of Epidemiology



Note: full paper requires paid subscription
"Cancer survival has become a key metric to assess the performance of health systems in delivering cancer care, both as part of national cancer programmes and in international comparisons. In this context, we need to know the survival of all cancer patients in the population, not just patients treated in a particular hospital or included in a clinical trial. Population-based survival estimates include all patients, including those who are not treated at all, either because their disease is too advanced at diagnosis for treatment of curative intent, or because they do not have access to the health-care system, or, in some countries, because of resource limitations such as the . . ."

Cancer Symptom Clusters: Old Concept But New Data



Abstract:
Individuals with cancer have multiple symptoms, which frequently co-occur. A nonrandom distribution of symptoms suggests a common mechanism. Symptom clusters (SCs) were considered part of various syndromes in the early years of medicine. The SC concept in clinical medicine is old. Symptom clusters were commonly described in the psychology/psychiatry and neurology literature. Symptom cluster may be defined either clinically or statistically. Statistically derived clusters can differ from clinically defined clusters. The clinical importance of statistically derived clusters is unclear. Pain-insomnia-fatigue and pain-depression-fatigue are commonly recognized clinical clusters. Nausea-vomiting and anxiety-depression are also statistically observed clusters.

Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy



Note: small study  
Background: Patients with recurrent ovarian cancer often achieve partial response following chemotherapy, resulting in persistent small volume disease. After completion of treatment, the dilemma of when to initiate subsequent chemotherapy arises. Identification of biomarkers that could be used to predict when subsequent treatment is needed would be of significant benefit. Design: ...A subgroup of patients provided plasma (blood) samples within which a panel of angiogenic biomarkers was quantified.  

Diabetes Raises Risk For Post-Surgical Mortality In Cancer Patients



"Care of diabetes before, during and after surgery is very important," Dr. Yeh said. "It should be part of the preoperative discussion."

Mutations in gene protecting body leads to development of cancer



Note: the PTEN mutation has and is being widely studied in ovarian cancer

"The study examined mutations in a gene called PTEN. People who inherit a mutated copy of this gene have Cowden syndrome, a condition that carries a high risk of cancer in a number of organs, including the breast, thyroid and ovary. In addition, PTEN is frequently mutated in normal body cells leading to prostate, lung and pancreatic cancers."

Myriad Loses Ruling Over Breast Cancer-Gene Patents (Update3) - BusinessWeek news article March 29, 2010



"The case is sure to be appealed to a court in Washington that specializes in patent law, and most likely to the Supreme Court.....
Years of Litigation:
He said today’s decision sets the stage for years of litigation to determine where the line is between what’s eligible for patents and what is not."

Medication errors involving oral chemotherapy - Cancer



Anxiety disorders in advanced cancer patients - Cancer



Combination IV paclitaxel, carboplatin showed viability at certain doses for gynecologic cancers



Daniel L. Clarke-Pearson Elected 42nd President of The Society of Gynecologic Oncologists - press release



Patient-caregiver concordance in symptom assessment and improvement in outcomes for patients undergoing cancer chemotherapy.



Simulation in surgical education -- Canadian Medical Association Journal



Note: for subscribers only

Monday, March 29, 2010

full free access: The detection, treatment, and biology of epithelial ovarian cancer



Note: click on 'pdf' for access to the full paper

Review
The detection, treatment, and biology of epithelial ovarian cancer

Jennifer A.A. Gubbels email, Nick Claussen email, Arvinder K. Kapur email, Joseph P. Connor email and Manish S. Patankar email

Journal of Ovarian Research 2010, 3:8doi:10.1186/1757-2215-3-8
Published: 29 March 2010
Abstract (provisional)

Ovarian cancer is particularly insidious in nature. Its ability to go undetected until late stage coupled with its non-descript signs and symptoms make it the seventh leading cause of cancer related deaths in women. Additionally, the lack of sensitive diagnostic tools and resistance to widely accepted chemotherapy regimens make ovarian cancer devastating to patients and families and frustrating to medical practitioners and researchers. Here, we provide an in-depth review of the theories describing the origin of ovarian cancer, molecular factors that influence its growth and development and standard methods for detection and treatment. Special emphasis is provided to interactions between ovarian tumors and the innate and adaptive immune system and attempts that are currently underway to devise novel immunotherapeutic approaches for the treatment of ovarian tumors.

Report: Tens of millions still opening junk e-mail | Security - CNET News



Note: for computer information CNET is a very good and reliable site

Genomics - HuGENet



See website for further information:

Population Research
Human Genome Epidemiology Network
(HuGENet™)

HuGENetIn 1998, the National Office of Public Health Genomics established the Human Genome Epidemiology Network (HuGENet™) to help translate genetic research findings into opportunities for preventive medicine and public health by advancing the synthesis, interpretation, and dissemination of population-based data on human genetic variation in health and disease.

HuGENet™ is interested in establishing collaborations with individuals and organizations working on population-based research involving genetic information. Learn how to participate in HuGENet™.

EPGM-Munich Oncology - Gynecologic Oncology - webcasts from November 2009 (variety of topics included)



Note: free to view/no passwords required

Placebo Eases Cancer-Related Fatigue - Dr Markman/video



Note: site requires sign on/password - free
short video with Dr Markman - March 26, 2010

New supportive care assessment guideline available | Canadian Partnership Against Cancer



Note: search results show there is no reference either in the body of the paper nor in the references section to ovarian cancer

"Conclusion
Despite limitations in the research, there is reasonable evidence that psychosocial
and supportive care needs are under-addressed, that assessment improves patient
outcomes, and that some screening for distress and psychosocial assessment tools
have effective psychometric properties that help to “red flag” patients and support
comprehensive assessment. The recommendations in this guideline have been
designed to explain, ignite, and support the need for quality psychosocial health care
needs assessment and screening for distress in persons living with cancer. Using an
evidence base that is grounded in research and clinical practice, they stress the
importance of assessment as a first step in the explication of need and the
implementation of appropriate interventions. At the same time, this document has
suggested a range of important considerations as the field moves forward – from
needs assessment, clinical service provision, resource allocation, intervention, followup,
and outcome evaluation, to related research, and more. We believe the adoption
of these recommendations into cancer practice will bring us one step closer to a
person-focused cancer system that can improve patient and family experience of
living with cancer."

Obama Chooses Health Policy Scholar as the Director for Medicare and Medicaid - NYTimes.com



Note: I have met Dr Berwick (via WHO Patient Safety), an extraordinarily compassionate individual

"WASHINGTON — President Obama will soon name Dr. Donald M. Berwick, an iconoclastic scholar of health policy, to run Medicare and Medicaid, the programs that serve nearly one-third of all Americans, administration officials said Saturday.

Dr. Berwick, a pediatrician, is president of the Institute for Healthcare Improvement in Cambridge, Mass. He has repeatedly challenged doctors and hospitals to provide better care at a lower cost...."

"Dr. Berwick has denounced “the insanity of health care that costs too much and achieves too little.” But at the same time, he celebrates the work of hospitals that have reduced medical errors and deaths by the systematic application of proven techniques. And he wants to disseminate the secrets of communities that provide high-quality care at low cost."

A systematic literature review of vitamin D and ovarian cancer.



CONCLUSION: There is no consistent or strong evidence to support the claim made in numerous review articles that vitamin D exposures reduce the risk for ovarian cancer occurrence or mortality.

Sunday, March 28, 2010

Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma



"The histopathological diagnosis of high-grade endometrioid and serous carcinoma of the ovary is poorly reproducible under the current morphology based classification system, especially for anaplastic, high-grade tumours.......In EOCs, WT1 protein is observed in the majority of serous carcinomas and in up to 30% of endometrioid carcinomas. It is unclear whether the latter is a reflection of the actual incidence of WT1 protein expression in endometrioid carcinomas, or whether a significant number of high-grade serous carcinomas have been misclassified as endometrioid carcinoma........It was found that nuclear WT1 protein expression can identify misclassified high-grade endometrioid carcinomas and these tumours should be reassigned to serous histotype. Although low-grade endometrioid carcinomas rarely progress to high-grade carcinomas, a combined WT1-negative, TP53-positive immunophenotype may identify an uncommon high-grade subtype of ovarian endometrioid carcinoma."

Sleep disturbances in asymptomatic BRCA1/2 mutation carriers: women at high risk for breast-ovarian cancer



"Fatigue and carrier status were significant predictors of sleep quality, accounting for 15.7% of the variance.
In conclusion, asymptomatic BRCA1/2 carriers experience poor sleep quality compared to non-carriers and controls. Our study design is unique in that it offers insight regarding the nature of being an asymptomatic carrier, and affords the opportunity to examine factors that may contribute to the development of insomnia in women at risk for breast-ovarian cancer."

Saturday, March 27, 2010

full access: Trastuzumab (Herceptin) sensitizes ovarian cancer cells to EGFR-targeted therapeutics



In research:

Background:  Early studies have demonstrated comparable levels of HER2/ErbB2 expression in both breast and ovarian cancer. Trastuzumab (Herceptin), a therapeutic monoclonal antibody directed against HER2, is FDA-approved for the treatment of both early and late stage breast cancer. However, clinical studies of trastuzumab in epithelial ovarian cancer (EOC) patients have not met the same level of success. Surprisingly, however, no reports have examined either the basis for primary trastuzumab resistance in ovarian cancer or potential ways of salvaging trastuzumab as a potential ovarian cancer therapeutic.

JAMA -- Ensuring Integrity in Industry-Sponsored Research: Primum Non Nocere, Revisited, March 24/31, 2010 (extract)



"The most fundamental principle of medicine, primum non nocere, holds for every physician, whether functioning as a clinician providing direct patient care; as a researcher, reviewer, or editor involved in medical publishing; or as an administrator overseeing an academic institution, health care organization, or pharmaceutical company research program. In all situations affecting patients, physicians must do no harm.

The Commentary in this issue of JAMA by Nissen describes a disturbing example of inappropriate conduct surrounding an industry-sponsored clinical trial of rosiglitazone and reveals a situation in which concerns about preserving market share apparently trumped concerns about the potential for causing patient harm. Analyzing this situation and others involving misleading reporting and possible misrepresentation of industry-sponsored research has become only too common, and it appears that physicians functioning at several levels failed to put the well-being of patients first."

Tweet Cloud (for fun)




Vitamin E neuroprotection for cisplatin neuropathy: A randomized, placebo-controlled trial -- Neurology



Conclusions: This phase III study confirms the neuroprotective role of vitamin E against cisplatin peripheral neurotoxicity. Vitamin E supplementation should be adopted in patients receiving cisplatin-based chemotherapy.

Friday, March 26, 2010

Arrayit Signs on Docro to Help Ovarian Cancer Diagnostic Gain FDA Clearance GenomeWeb




Vermillion's OVA1 became the first protein-based in vitro diagnostic multivariate index assay to receive FDA clearance [See PM 09/17/09] and earlier this month it and Quest Diagnostics began marketing OVA1.

In addition, Correlogic is in discussions with the FDA about its OvaCheck test,

and

Healthlinx, which launched its test called OvPlex in the UK in February, has said that it may launch the test in the US next year, if it receives regulatory approval.

This week, Arrayit said that OvaDx will be the market's first "comprehensive diagnostic for ovarian cancer" and will be targeted to all women over the age of 35.

Delivering consensus from the Asian Oncology Summit 2009 : The Lancet Oncology



The webtable shows a breakdown of the country of origin of all participants in the workshops and among the authorship of the resultant papers. Participants represented 21 different countries, of which 15 were Asian. Each workshop had about 40—100 attendees, and the majority of authors work in Asian hospitals. The manuscripts are a wonderful testament to the resources and expertise available in Asia, and we hope they will provide a valuable resource of information to inform practice and provide a foundation for future developments of oncology services throughout the region.
The 2nd Asian Oncology Summit will be held in Bali, Indonesia, on April 9—11, 2010. See www.asianoncologysummit.com for more details.

The Lancet Student » Lancet Seminar: Colorectal cancer including genetics (eg: Lynch Syndrome)




Oprah picks inspirational painting from Dallas artist Shannon Kincaid




From unwanted interference to indispensable partner - Masterpiece - Issues 35 - Articles - Cancer World - Education & knowledge through people & facts



From unwanted interference to indispensable partner

"Three years after taking up the presidency of Europe’s first international breast cancer coalition, Gloria Freilich faced her most embarrassing moment. It was 1997 and she had started to address a major meeting of oncologists in Lisbon, talking about her new organisation, designed by women for women, called Europa Donna. Then a doctor stood up and challenged her. What right did a layperson, he asked, have to address a thousand oncologists at a medical meeting?..."

The ethics of dietary supplements and natural health products in pharmacy practice: a systematic documentary analysis



Thursday, March 25, 2010

CBC Toronto | Features | First, the Bad News - audio (Princess Margaret Hospital)



Note: Dr Oza speaks briefly about a new endometrial cancer therapy and mentions ovarian cancer

CCR Connections (News NIH) - Big Things in Small Packages: Small RNAs Play a Big Role in Cancer Biology



"Exquisitely tuned gene expression is essential to orchestrate both the development and functioning of the myriad cell types in the human body. When that tuning goes awry, one result is cancer. Small microRNAs (miRNAs) have emerged relatively recently as key modulators of gene expression, acting at a stage between transcription of the genes and translation into proteins. Although they are tiny, miRNAs—at a little over 20 nucleotides long—pack a big punch since each regulates a variety of genes, and they are involved in diverse pathological processes, including cell proliferation and death...."

CCR Connections (News at NIH) - A Cure for the Incurable? Using the Body's Immune System to Treat Metastatic Cancers



Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine




Age and gender differences in symptom intensity and symptom clusters among patients with metastatic cancer



Note: abstract denotes 'common cancers' only, no reference to ovarian cancer

"Analyses of symptom clusters revealed that fatigue and drowsiness were included in the cluster of pain, nausea, and appetite in younger but not older patients. In men, pain clustered together with depression and anxiety; for women, physical and psychological symptoms formed separate clusters.

CONCLUSIONS: In patients with advanced cancers, symptom patterns differ according to age and gender. Palliative interventions tailored for symptoms that are more prominent in specific patient subgroups may offer greater therapeutic benefit."

abstract: Ensuring a healthy and productive workforce: comparing the generosity of paid sick day and sick leave policies in 22 countries




Wednesday, March 24, 2010

full access: NEJM -- Untangling the Web -- Patients, Doctors, and the Internet




March 24th: No Link to Femur Fractures Found with Bisphosphonates - in Endocrinology, Osteoporosis



Action Points  
  • Explain to interested patients that although this study did not find a link, some case reports have suggested that atypical fractures of the femur may be more common in patients treated with bisphosphonates, the most common drugs for treating osteoporosis.
  • Explain that the FDA has begun a formal safety inquiry into this potential risk, but it has emphasized that it has not yet found evidence to suggest that physicians or patients should avoid these drugs.

NIH Genetic Testing Registry



With an increasing number of genetic tests available, the National Institutes of Health (NIH) recognizes the importance of making information about these tests easily accessible to researchers, patients, consumers, health care providers, payers, and others. Therefore, NIH is initiating the development of the Genetic Testing Registry (GTR), an online resource that will provide a centralized location for test developers and manufacturers to voluntarily submit test information such as indications for use, validity data, and evidence of the test’s usefulness. The overarching goal of the GTR is to advance the public health and research into the genetic basis of health and disease.

As such, the Registry will have several key functions:

* Encourage providers of genetic tests to enhance transparency by publicly sharing information about the availability and utility of their tests;
* Provide an information resource for the public, including researchers, health care providers and patients, to locate laboratories that offer particular tests; and
* Facilitate genetic and genomic data-sharing for research and new scientific discoveries.

Interacting with stakeholders—such as laboratory test developers, manufacturers, health care providers, patient and consumer groups, and researchers—will be a critical part of developing the GTR.

NIH Announces Genetic Testing Registry, March 18, 2010 News Release - National Institutes of Health (NIH)



NIH Announces Genetic Testing Registry
Database to Fill Information Gaps and Serve as Research Resource

The National Institutes of Health announced today that it is creating a public database that researchers, consumers, health care providers, and others can search for information submitted voluntarily by genetic test providers. The Genetic Testing Registry (GTR) aims to enhance access to information about the availability, validity, and usefulness of genetic tests. More information about the Genetic Testing Registry and NCBI is available at: http://www.ncbi.nlm.nih.gov/gtr/.

PLoS ONE: Bias Due to Changes in Specified Outcomes during the Systematic Review Process



Thermo Fisher Extends Biomarker Pact with Universities News | Proteomics | GenomeWeb



"NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that it has extended a biomarker research effort with George Mason University's Center for Applied Proteomics and Molecular Medicine (CAPMM), Johns Hopkins University, and Toronto's University Health Network (UHN)."

China Continues to Consult NCCN for Guidance on Cancer Treatment



"Programs continue into the month of April; NCCN Guidelines Symposia on Ovarian Cancer, Cervical Cancer, and Head & Neck Cancers will be held on April 17 in Beijing."

Underdiagnosis of Lynch Syndrome Involves More than Family History Criteria



CONCLUSIONS:
Lynch syndrome is under-recognized, even when patients have clear criteria unrelated to family history. Multifaceted strategies focused on reducing providers' cognitive errors and harnessing EHR capabilities to improve recognition of Lynch syndrome are needed."

financial news - Picoplatin - UPDATE 3-Poniard suspends regulatory efforts on key drug | Reuters



Note: read the whole article "The company said it would focus its resources on developing clinical strategies for picoplatin in small cell lung cancer, as well as colorectal, prostate and ovarian cancers."

Information for consumers | The Cochrane Collaboration




The Cochrane Collaboration | Working together to provide the best evidence for health care



The Cochrane Collaboration is an international, independent, not-for-profit organisation of over 27,000 contributors from more than 100 countries, dedicated to making up-to-date, accurate information about the effects of health care readily available worldwide.

We are world leaders in evidence-based health care

Our contributors work together to produce systematic assessments of healthcare interventions, known as Cochrane Reviews, which are published online in The Cochrane Library. Cochrane Reviews are intended to help providers, practitioners and patients make informed decisions about health care, and are the most comprehensive, reliable and relevant source of evidence on which to base these decisions.

A Study of Stimuvax® in Combination With Hormonal Treatment Versus Hormonal Treatment Alone for First-line Therapy of Endocrine-sensitive Advanced Breast Cancer - Full Text View - ClinicalTrials.gov



Note: actively recruiting as at March 24th, 2010
A Study of Stimuvax® in Combination With Hormonal Treatment Versus Hormonal Treatment Alone for First-line Therapy of Endocrine-sensitive Advanced Breast Cancer - Full Text View - ClinicalTrials.gov

Merck KGaA halts cancer vaccine trial - MarketWatch



"STRIDE is a randomized, double-blind, controlled, multi-center Phase III study designed to determine if Stimuvax can extend progression free survival in patients treated with hormonal therapy who have inoperable, locally advanced, recurrent or metastatic breast cancer."

website: Australian Society of Gynaecologic Oncologists ASGO



Search of: COTI-2 - Search Details - ClinicalTrials.gov



Found no studies with search of: COTI-2

financial news: Critical Outcome Technologies Inc. Invited to Present Data on COTI-2 at US Oncology Summit (in research)



Note: in research

About COTI-2

COTI-2 is a novel small molecule that acts by inhibition of Akt/PKB (Protein kinase B) phosphorylation that leads to caspase-9 activation in cancer cells resulting in apoptosis or programmed cell death. COTI-2 is easily synthesized and has good in vitro and in vivo efficacy against multiple cancers including small cell lung, non-small cell lung, colon, brain, ovarian, endometrial and pancreatic cancers. COTI-2 test results show it to be highly effective as a single agent therapy and as a combination therapy in a number of animal models of human cancers. COTI-2 differs from other cancer treatments in that other treatments involve the killing of all growing and dividing cells in the body resulting in significant toxic side effects while COTI-2 appears to target and destroy cancer cells only and has demonstrated low toxicity in normal human cells compared to human cancer cells.

Current Controlled Trials - Database of Clinical Trials - Europe



Note: this is a database of European clinical trials - the database has been around for many years  

Search for trials: Trials uniquely identified by an ISRCTN Search across multiple registers (including the NHS in England and US ClinicalTrials.gov)

Trends in the survival of patients diagnosed with cancer in female genital organs in the Nordic countries 1964-2003 followed up to the end of 2006



Primary peritoneal and ovarian cancers: an epidemiological comparative analysis



"The difference in the risk factor associations between invasive serous PPC and EOC cancers suggests divergent molecular development of peritoneal and ovarian cancers. A larger study to determine risk factors for invasive serous PPC is warranted."

Tuesday, March 23, 2010

NCI Cancer Bulletin: Training Providers and Patients to Talk about End-of-Life Care




March 23, 2010 - NCI: Fatigue: Is it Normal or Pathological? And How Can We Best Treat It?



"Despite years of scientific study of cancer-related fatigue (CRF), questions related to its definition, measurement, underlying mechanisms, and effective interventions remain unanswered. Yet, the high prevalence of CRF and its negative effects on quality-of-life outcomes, including work and family functioning, make it a critical problem for cancer patients and survivors. Clearly, more research is needed to reduce morbidity associated with this symptom.

To address this, on April 13 and 14, NCI’s Symptom Management and Health-related Quality of Life Steering Committee will convene a closed-attendance state-of-the-science meeting on CRF, which I will chair. During this meeting, we will summarize the science, address gaps in knowledge that require further study, and develop a focused agenda for future research......

Perhaps the best way to appreciate the urgent need to better understand and treat CRF is from the perspective of cancer patients and survivors who have experienced it. In discussing CRF, invariably they talk about their inability to get out of the house, work, cook meals and do dishes, get up the stairs to go to bed, or do half the things they did before. It is for these reasons that scientists need to fill the gaps in our knowledge of CRF."

(free) Registration page: Triple-Negative Breast Cancer: Genetic Risk and Treatment Updates - U of Michigan/Sunnybrook Toronto



April teleconference on triple-negative breast cancer risk and updates

Triple-Negative Breast Cancer: Genetic Risk and Treatment Updates

Join Living Beyond Breast Cancer and The Triple Negative Breast Cancer Foundation for our next free teleconference, Triple-Negative Breast Cancer: Genetic Risk and Treatment Updates, from 12:00 p.m. to 1:15 p.m. Eastern Daylight Time (EDT) on Thursday, April 15.

SGO: Targeting Platelets May Help Ovarian Cancer - in Meeting Coverage




MedPage Today Action Points
  • Explain to patients that abnormal platelet levels or activity may play a role in ovarian cancer.

  • The findings are based on a retrospective cohort study and laboratory experiments involving a preclinical model of ovarian cancer.

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered preliminary until published in a peer-reviewed journal.

Stanford University Researcher and Hemispherx Biopharma Consultant Present New Integrative Immunotherapy Approach - news item



"PHILADELPHIA, Mar 23, 2010 (GlobeNewswire via COMTEX) -- Hemispherx Biopharma, Inc. announced today the publication of an editorial entitled "TLR3 agonists as immunotherapeutic agents," published in the March 15, 2010 edition of Immunotherapy (2010) 2(2), 137-140, co-authored by Jonathan S. Berek, MD, Chairman, Stanford University School of Medicine Department of Obstetrics and Gynecology, and Christopher F. Nicodemus, MD, Chairman and Chief Scientific Officer, Advanced Immune Therapeutics, Inc., and HEB Consultant.
Drs. Berek and Nicodemus have collaborated for more than a decade seeking to identify novel strategies to mobilize immunity to treat cancer and have conducted and published numerous preclinical and clinical studies, most notably in the field of ovarian cancer. Their long standing research interests form the basis for an active collaboration with the Company to evaluate the potential for Ampligen(R) (rintatolimod, Poly I : Poly C12U) and TLR3 agonists as cancer immunotherapeutics...."

Sexuality and intimacy after gynecological cancer



"The essential part of success is the providers appreciation of this serous problem and willingness and comfort in addressing it."

Doubling time of serum CA125 is an independent prognostic factor for survival in patients with (early stage) ovarian cancer relapsing after first-line chemotherapy



"There is a lack of data in early-stage ovarian cancer on the pattern of CA-125," said Chan. "Previous studies generally had no comprehensive staging and no central pathology review."
The Gynecologic Oncology Group (GOG) 157 trial provided an opportunity to examine the change in CA-125 and its relationship to outcomes in women with early-stage ovarian cancer. The trial involved 427 women with stage I-II epithelial ovarian cancer. They were randomized to receive three or six cycles of chemotherapy with carboplatin and paclitaxel.
All patients had detailed surgical staging before randomization. Chan said detailed information about CA-125 levels was available for 350 participants in the trial.

Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours



Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.

CONCLUSIONS: Belinostat is well tolerated in both patient groups and shows some activity in patients with micropapillary (LMP) disease.

Endometrial and ovarian carcinomas with undifferen... [Mod Pathol. 2010] - PubMed result



"Carcinomas of the endometrium and ovary with undifferentiated components are uncommon neoplasms that are likely underdiagnosed.
They are important to recognize as they have been shown to be clinically aggressive.....Most patients (58% of endometrial and 83% of ovarian carcinomas with undifferentiated components) presented at advanced stages (FIGO III-IV).. ... The tumors were frequently misdiagnosed; they received a wide range of diagnoses, including FIGO grade 2 or 3 endometrioid carcinoma, carcinosarcoma, high-grade sarcoma including endometrial stromal sarcoma, neuroendocrine carcinoma, lymphoma, granulosa cell tumor and epithelioid sarcoma.... They were predominantly negative for neuroendocrine markers, smooth muscle markers and estrogen receptor/progesterone receptor. Mismatch repair protein expression by immunohistochemistry was evaluated in 17 cases, and 8 (47%) were abnormal (7 with loss of MLH1/PMS2 and 1 with MSH6 loss)....Endometrial and ovarian carcinomas with undifferentiated components have a broad histologic differential diagnosis, but they show specific histologic features that should enable accurate diagnosis.
These tumors can occur in young women, may be associated with microsatellite instability and behave in a clinically aggressive manner."
J Modern Pathology

Canadian Medical Association Journal: Opinion 'No more Dithering on e-health"



No more dithering on e-health: let’s keep patients safe instead
March 1, 2010

"Our slow progress on electronic health records should act as a call to action. An electronic health record system with access for everyone — family physicians, consultants, pharmacists, hospitals, managers and researchers — will save lives and improve health outcomes. Canadians deserve nothing less."

Monday, March 22, 2010

Medical News: SGO: Angiogenesis Inhibitor Scores Split Decision - in Meeting Coverage, SGO (enzastaurin and bevacizumab (Avastin)




Andrew Pollack Versus Personal Genomics? Not Quite GenomeWeb




Red Cell Distribution Width and the Risk of Death in Middle-aged and Older Adults




Philadelphia News Mourns Professor’s Death Karen Buhler-Wilkerson (nurse/author)




Proof In Humans Of RNA Interference Using Targeted Nanoparticles - Health News - redOrbit



In research

The discovery of RNA interference, the mechanism by which double strands of RNA silence genes, won researchers Andrew Fire and Craig Mello the 2006 Nobel Prize in Physiology or Medicine.... "RNAi is a new way to stop the production of proteins," says Davis. What makes it such a potentially powerful tool, he adds, is the fact that its target is not a protein. The vulnerable areas of a protein may be hidden within its three-dimensional folds, making it difficult for many therapeutics to reach them. In contrast, RNA interference targets the messenger RNA (mRNA) that encodes the information needed to make a protein in the first place. "In principle," says Davis, "that means every protein now is druggable because its inhibition is accomplished by destroying the mRNA. And we can go after mRNAs in a very designed way given all the genomic data that are and will become available."

Arrayit Corporation - FDA / OvaDx - financial news



"Arrayit's OvaDx Pre-Symptomatic Ovarian Cancer Test will be the market's first comprehensive diagnostic screen for ovarian cancer, and will be recommended for all women over the age of 35. OvaDx uses approximately 100 proteomic biomarkers in a microarray format to identify molecular beacons of ovarian cancer that accumulate in the bloodstream as a result of the body's natural immune response to developing ovarian tumors. Arrayit's microarray test, which detects both early and late stage ovarian cancer..."cont'd

Medical News: SGO: Test Aids Preop Decisions About Ovarian Masses - in Meeting Coverage, SGO - OVA1



"...However, the test's low specificity raised some concern, as verbalized by an invited discussant of the study." MedPage Today Action Points * Explain to patients that in this study, use of a laboratory test improved the presurgical evaluation of ovarian tumors compared with physician clinical assessment alone. * Note that the test is for preoperative assessment of ovarian tumors and is not a screening or diagnostic test. * Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.

Medical News: SGO: Low Cancer Risk with Septated Ovarian Tumors - in Meeting Coverage, SGO




Sunday, March 21, 2010

The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review



Centre for Review and Dissemination - Database of Abstracts of Reviews of Effects (DARE)

Authors' objectives:

To determine the efficacy of specialised care for patients with ovarian cancer.
Authors' conclusions:The outcome of ovarian cancer was better when treatment was provided in specialised settings (gynecologic oncologists or in specialised hospitals) than that provided in non-specialised settings.

CRD commentary:
"Given the limitations and the lack of reported methodology in the review process, although the results appeared promising the authors conclusion appears to be overstated."

OU Medical Center and Edmond Medical Center To Combine



OKLAHOMA CITY/EDMOND Note: includes information on womens' health including gynecologic oncology

Medical News March 21st : SGO: Hunt for Ovarian Regimen Focuses on Carboplatin - in Meeting Coverage, SGO




2009 media item: HST Global and HMD team up to develop curriculum for FIT protocol



" HSTC) today announced a Partnership with Dr. James W. Forsythe to facilitate the development of a curriculum for the licensing and/or certification to administer Dr. Forsythe’s immune therapy in clinics to be built or acquired by HST Global, Inc. Dr. Forsythe brings over thirty years of medical and research experience including expertise in the research and clinical application of his “Forsythe Immune Therapy” (FIT).
As previously announced, James W. Forsythe, MD, HMD, board certified oncologist and a member of HST Global Inc.’s Board of Directors and Head of the Scientific Advisory Board, was featured in Suzanne Somers’ book Knockout. Due to the overwhelming response to the information and protocol featured in Ms. Somers’ book, Dr. Forsythe’s clinic has become inundated with new patient requests and referrals. Due to this dramatic increase in both new patient inquiries and volume, it has become necessary to increase the staff at Dr Forsythe’s facility, The Cancer Screening and Treatment Center of Nevada."

HST Global - media item "FIT protocol" Dr Forsythe



March 9, 2010
HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC)today announced that Dr. James Forsythe, MD, HMD, is experiencing continuous success with his Forsythe Immune Therapy (FIT) Protocol. Dr. James Forsythe, MD, HMD, is a board certified oncologist and a member of HST Global Inc.’s Board of Directors and Scientific Advisory Board.

Dr. Forsythe’s existing study is meeting with 70-80% efficacy in clinical treatment of Stage IV cancers in a test of 450 patients. The highlight of the study is in stage IV prostate cancer where they have met with 86% efficacy with prostate cancer patients over 55 months through the application of his "FIT" Protocol.

Ronald Howell President and CEO of HST Global, Inc. stated, "We are encouraged by the continued success Dr. Forsythe is experiencing with his FIT protocol. The updated study results demonstrate the efficacy of the FIT Protocol."

Pregabalin for acute and chronic pain in adults - Cochrane Collaboration review



Note: includes numerous comments by a variety of healthcare professional disciplines

BACKGROUND:
Antiepileptic drugs have been used in pain management since the 1960s. Pregabalin is a recently developed antiepileptic drug also used in management of chronic neuropathic pain conditions.

CONCLUSIONS:
Pregabalin has proven efficacy in neuropathic pain conditions and fibromyalgia. A minority of patients will have substantial benefit with pregabalin, and more will have moderate benefit. Many will have no or trivial benefit, or will discontinue because of adverse events. Individualisation of treatment is needed to maximise pain relief and minimise adverse events. There is no evidence to support the use of pregabalin in acute pain scenarios.

Co-operation between patient organisations and the drug industry in Finland